Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

Clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR associated protein 9 (Cas9)-based therapeutics, especially those that can correct gene mutations via homology-directed repair, have the potential to revolutionize the treatment of genetic diseases. However, it is challenging to develop homology-directed repair-based therapeutics because they require the simultaneous in vivo delivery of Cas9 protein, guide RNA and donor DNA. Here, we demonstrate that a delivery vehicle composed of gold nanoparticles conjugated to DNA and complexed with cationic endosomal disruptive polymers can deliver Cas9 ribonucleoprotein and donor DNA into a wide variety of cell types and efficiently correct the DNA mutation that causes Duchenne muscular dystrophy in mice via local injection, with minimal off-target DNA damage.Gold nanoparticles carrying Cas9 ribonucleoprotein and donor DNA, and complexed with endosomal disruptive polymers, correct the DNA mutation that causes Duchenne muscular dystrophy in mice, with minimal off-target effects.

[1]  Andrew Emili,et al.  Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. , 2014, ACS nano.

[2]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[3]  W. Chan,et al.  DNA assembly of nanoparticle superstructures for controlled biological delivery and elimination , 2014, Nature nanotechnology.

[4]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[5]  Sung Tae Kim,et al.  Gold nanoparticles for nucleic acid delivery. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  A. Rabinowitz,et al.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Mirkin,et al.  Spherical Nucleic Acids as a Divergent Platform for Synthesizing RNA–Nanoparticle Conjugates through Enzymatic Ligation , 2014, ACS nano.

[8]  George Church,et al.  Optimization of scarless human stem cell genome editing , 2013, Nucleic acids research.

[9]  Xiquan Liang,et al.  Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX , 2016, Biotechnology Letters.

[10]  Jennifer A. Doudna,et al.  DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 , 2014, Nature.

[11]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[12]  Jingying Liu,et al.  Protein-gold nanoparticle interactions and their possible impact on biomedical applications. , 2017, Acta biomaterialia.

[13]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[14]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[15]  Ke Zhang,et al.  Mitochondrial fusion but not fission regulates larval growth and synaptic development through steroid hormone production , 2014, eLife.

[16]  Jay C. Sy,et al.  Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. , 2008, Nature materials.

[17]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[18]  S. Fukushima,et al.  Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. , 2008, Journal of the American Chemical Society.

[19]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[20]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[21]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[22]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[23]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[24]  Jun Yan,et al.  Corrigendum: Differential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammation , 2016, Nature Communications.

[25]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[26]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[27]  Paula T Hammond,et al.  Layer-by-layer platform technology for small-molecule delivery. , 2009, Angewandte Chemie.

[28]  G. Pavlath,et al.  Cell Fusion in Skeletal Muscle: Central Role of NFATC2 in Regulating Muscle Cell Size , 2003, Cell cycle.

[29]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[30]  J. Kornegay,et al.  Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  Suresh Ramakrishna,et al.  Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA , 2014, Genome research.

[32]  Samuel H Sternberg,et al.  Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9 , 2016, Nature Communications.

[33]  Jacob E Corn,et al.  Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA , 2016, Nature Biotechnology.

[34]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[35]  Renzhi Han,et al.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  N. Nishiyama,et al.  Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Jacob E Corn,et al.  Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering , 2017, eLife.

[38]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[39]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[40]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[41]  David T. Okou,et al.  Microarray‐based mutation detection in the dystrophin gene , 2008, Human mutation.

[42]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[43]  Chao Wang,et al.  Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. , 2015, Angewandte Chemie.

[44]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .

[45]  Satyakam Bhagavati,et al.  Exon-skipping therapy for Duchenne muscular dystrophy , 2012, The Lancet.